open access

Vol 1, No 1 (2005)
Review paper
Published online: 2005-05-17
Get Citation

The colony stimulating factors for the management of chemotherapy-induced neutropenia

David C. Dale
Onkol. Prak. Klin 2005;1(1):49-53.

open access

Vol 1, No 1 (2005)
REVIEW ARTICLES
Published online: 2005-05-17

Abstract

Neutropenia is without any doubts the most severe and risky side effect of chemioterapy. In the 60-s of the 20 th century the colony stimulating factors (CSFs) were discovered. The principal use of the CSFs in cancer treatment is to accelerate marrow recovery after chemotherapy, thus shortening the duration of severe neutropenia and reducing the risk of bacterial and fungal infections. The strongest evidence for the use of CSFs in cancer treatment is for prevention of febrile neutropenia after myelotoxic chemotherapy. At the beginning of anticancer chemioterapy the the doses were applied to let marrow recovery after each course of treatment. With the development of the hematopoietic growth factors, however, it became possible to compress treatment schedules and give standard doses of chemotherapy agents on an accelerated schedule, i.e., at less than three-week intervals. The use of the colony stimulating factors to prevent chemotherapy-induced neutropenia is based upon the physiological understanding of the regulation of neutrophil production and deployment in the body under normal conditions and in response to infections. The availability of the CSFs has greatly improved our treatment of patients with cancer. It is possible that innovations in the use of these agents will lead to further improvements in cancer treatment soon.

Abstract

Neutropenia is without any doubts the most severe and risky side effect of chemioterapy. In the 60-s of the 20 th century the colony stimulating factors (CSFs) were discovered. The principal use of the CSFs in cancer treatment is to accelerate marrow recovery after chemotherapy, thus shortening the duration of severe neutropenia and reducing the risk of bacterial and fungal infections. The strongest evidence for the use of CSFs in cancer treatment is for prevention of febrile neutropenia after myelotoxic chemotherapy. At the beginning of anticancer chemioterapy the the doses were applied to let marrow recovery after each course of treatment. With the development of the hematopoietic growth factors, however, it became possible to compress treatment schedules and give standard doses of chemotherapy agents on an accelerated schedule, i.e., at less than three-week intervals. The use of the colony stimulating factors to prevent chemotherapy-induced neutropenia is based upon the physiological understanding of the regulation of neutrophil production and deployment in the body under normal conditions and in response to infections. The availability of the CSFs has greatly improved our treatment of patients with cancer. It is possible that innovations in the use of these agents will lead to further improvements in cancer treatment soon.
Get Citation

Keywords

neutropenia; colony stimulating factors; chemotherapy; febrile neutropenia

About this article
Title

The colony stimulating factors for the management of chemotherapy-induced neutropenia

Journal

Oncology in Clinical Practice

Issue

Vol 1, No 1 (2005)

Article type

Review paper

Pages

49-53

Published online

2005-05-17

Bibliographic record

Onkol. Prak. Klin 2005;1(1):49-53.

Keywords

neutropenia
colony stimulating factors
chemotherapy
febrile neutropenia

Authors

David C. Dale

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl